ART

CTN 002: ddI, continued AZT

Double Blind Comparison of ddI and Continued Zidovudine (AZT) in Therapy of Patients with HIV-Related Immune Suppression: Trial results

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Fanconi syndrome due to ARVs in HIV-infected persons

Vicriviroc in HIV treatment-experienced people

Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects

Ritonavir-boosted elvitegravir versus raltegravir

A Multicenter, randomized, double-blind, double-dummy, phase 3 study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL)

Extended release nevirapine QD in treatment-naïve (VERxVE study)

A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada™ in antiretroviral therapy naïve HIV-1 infected patients. (VERxVE study)(Trial number 1100.1486)

Fosamprenavir and Ritonavir or Fosamprenavir Alone, in Pediatric Patients with HIV Infection

48-Week Study of GW433908 and Ritonavir or GW433908 Alone, Twice Daily in Pediatric Patients with HIV Infection.

ARIES Study

Atazanavir + Ritonavir + Abacavir/Lamivudine combination in HIV-1 infection